Domiciliary Management of Dental Erosion in Patients With GERD With Biomimetic Hydroxyapatite

Sponsor
University of Pavia (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT05371717
Collaborator
(none)
50
1
2
6
8.3

Study Details

Study Description

Brief Summary

The aim of the present study is to evaluate dental erosion in patients with gastroesophageal reflux disease (GERD).

Patients consenting to participate to the study will undergo periodontal evaluation at the baseline. Then, professional dental hygiene will be performed. Patients will be randomly assigned to:

  • Trial group: home oral hygiene with Biorepair Total Protection + Biorepair Shock Treatment twice a day

  • Control group: home oral hygiene with Biorepair Total Protection Patients will be evaluated after 1, 3 and 6 months from baseline.

Condition or Disease Intervention/Treatment Phase
  • Other: Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment
  • Other: Biorepair Total Protection
N/A

Detailed Description

The aim of the present study is to evaluate dental erosion in patients with gastroesophageal reflux disease (GERD).

Patients consenting to participate to the study will undergo periodontal evaluation at the baseline. Then, professional dental hygiene will be performed. Patients will be randomly assigned to:

  • Trial group: home oral hygiene with Biorepair Total Protection + Biorepair Shock Treatment twice a day

  • Control group: home oral hygiene with Biorepair Total Protection Patients will be evaluated after 1, 3 and 6 months from baselin

Study Design

Study Type:
Interventional
Actual Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Management of Dental Erosion in Patients With Gastroesophageal Reflux Disease With Biomimetic Hydroxyapatite Toothpaste
Actual Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Trial Group

Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment application

Other: Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment
Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.

Active Comparator: Control group

Domiciliary use of Biorepair Total Protection

Other: Biorepair Total Protection
Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.

Outcome Measures

Primary Outcome Measures

  1. Change of BEWE (Basic Erosive Wear Examination) [Study begin, 1, 3 and 6 months after the baseline]

    Scoring criteria (Barlet et al., 2008): 0: no erosive tooth wear; 1: initial loss of surface texture; 2: distinct defect, hard tissue loss < 50% of the surface area; 3: hard tissue loss ≥ 50% of the surface area. IntactTooth smartphone application will be used to calculate this index.

  2. Change in Schiff Air Index - Dental sensitivity test [Study begin, 1, 3 and 6 months after the baseline]

    Scoring criteria: 0: the subject did not respond to air blasting; the subject responded to air blasting; the subject responded to air blasting and requested discontinuation; the subject responded to air blasting, requested discontinuation and considered the stimulus to be painful.

  3. Change in Plaque Index (PI% - O' Leary Index) [Study begin, 1, 3 and 6 months after the baseline]

    Evaluation of the presence of plaque on the 4 surfaces of teeth on the total amount of dental surfaces. Formula = n ° sites with plaque / total n ° of dental surfaces x100

  4. Change in Bleeding Score (BS - Mombelli et al.) [Study begin, 1, 3 and 6 months after the baseline]

    Scoring criteria: 0: no bleeding isolated visible spots blood forms a confluent red line on the mucosal margin profuse and copious bleeding

  5. Laryngopharyngeal pH monitoring pH monitoring [Study begin, 1, 3 and 6 months after the baseline]

    Data was collected wirelessly for 24 hours and then analysed. Length, severity and number of reflux episodes were calculated. The RYAN score was used to evaluate for laryngopharyngeal acid reflux and was calculated for both the upright and supine positions. A RYAN score >9.4 in the upright position or >6.8 in the supine position was considered positive. Patients with a positive RYAN score in either the upright or supine positions were considered positive for laryngopharyngeal acid reflux.

  6. Erosion risk level [Study begin, 1, 3 and 6 months after the baseline]

    For each sextant, the highest BEWE value will be chosen. A mean of all the sextant values will be performed to calculate erosion risk level. IntactTooth smartphone application will be used to calculate this index.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patients with dental erosion

  • no proton pumps before pH examination

Exclusion Criteria:
  • no dental erosion

  • neurological and psychiatric diseases;

  • pregnant and/or breastfeeding women;

  • patients with poor compliance.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia Pavia Lombardy Italy 27100

Sponsors and Collaborators

  • University of Pavia

Investigators

  • Principal Investigator: Andrea Scribante, DDS, PhD, MS, University of Pavia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrea Scribante, Associate Professor, Principal Investigator, University of Pavia
ClinicalTrials.gov Identifier:
NCT05371717
Other Study ID Numbers:
  • 2022-GASTRO
First Posted:
May 12, 2022
Last Update Posted:
Jun 27, 2022
Last Verified:
Jun 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Andrea Scribante, Associate Professor, Principal Investigator, University of Pavia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 27, 2022